Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074599 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| SCHEMBL7876545 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| SCHEMBL31336702 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| SCHEMBL7599136 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL28520370 | 0.98 | ALDH1A1 (0.51) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| Phosphoric Acid SCHEMBL28688921 | 0.94 | ACP3 (0.50) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| SCHEMBL400880 | 0.90 | ALDH1A1 (0.56) | ALDH1A1MMEKMT2AMEN1MAPT | |
| SCHEMBL14017328 | 0.90 | ALDH1A1 (0.50) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| SCHEMBL4855809 | 0.90 | ALDH1A1 (0.50) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| SCHEMBL4854909 | 0.90 | ALDH1A1 (0.50) | ALDH1A1MMESIGMAR1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312646-A1 | ANTIBACTERIAL PEPTIDES | Universite de Bordeaux (FR) | 2023-10-05 | — | — | US | claimed |
| EP-4172174-A1 | ANTIBACTERIAL PEPTIDES | Centre National de la Recherche Scientifique (FR) | 2023-05-03 | — | — | EP | claimed |
| CN-114133398-B | Amino acid substituted acyclovir tricyclic nucleoside derivative and synthesis method and application thereof | 中南民族大学 | 2022-11-22 | — | — | CN | claimed |
| CN-114133398-A | Amino acid substituted acyclovir tricyclic nucleoside derivative and synthesis method and application thereof | 中南民族大学 | 2022-03-04 | — | — | CN | claimed |
| WO-2022002951-A1 | ANTIBACTERIAL PEPTIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-01-06 | — | — | WO | claimed |
| EP-3932935-A1 | ANTIBACTERIAL PEPTIDES | Centre National de la Recherche Scientifique (FR) | 2022-01-05 | — | — | EP | claimed |
| CN-104098650-B | The synthesis and application of the intermediate of Atosiban | 中国医学科学院药物研究所 | 2019-04-09 | — | — | CN | claimed |
| CN-109563144-A | Compound (I) | M3生物技术公司 | 2019-04-02 | — | — | CN | claimed |
| US-20230312646-A1 | ANTIBACTERIAL PEPTIDES | Universite de Bordeaux (FR) | 2023-10-05 | — | — | US | disclosed |
| EP-4172174-A1 | ANTIBACTERIAL PEPTIDES | Centre National de la Recherche Scientifique (FR) | 2023-05-03 | — | — | EP | disclosed |
| EP-4100042-A1 | REVERSE AMIDE-LINKED MELANOCORTIN RECEPTOR-SPECIFIC CYCLIC PEPTIDES | Palatin Technologies, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-114133398-B | Amino acid substituted acyclovir tricyclic nucleoside derivative and synthesis method and application thereof | 中南民族大学 | 2022-11-22 | — | — | CN | disclosed |
| CN-114133398-A | Amino acid substituted acyclovir tricyclic nucleoside derivative and synthesis method and application thereof | 中南民族大学 | 2022-03-04 | — | — | CN | disclosed |
| WO-2022002951-A1 | ANTIBACTERIAL PEPTIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-01-06 | — | — | WO | disclosed |
| EP-0345990-A2 | Polypeptide compounds | ZENECA LIMITED (GB) | 1989-12-13 | — | — | EP | disclosed |
| WO-1989010751-A1 | FUNCTIONALIZED PEPTIDYL AMINODIOLS AND -TRIOLS | ABBOTT LABORATORIES (US) | 1989-11-16 | — | — | WO | disclosed |
| EP-0341602-A2 | Renin-inhibiting functionalized peptidyl aminodiols and - triols | ABBOTT LABORATORIES (US) | 1989-11-15 | — | — | EP | disclosed |
| US-4837204-A | RENIN INHIBITORS; HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0315367-A2 | Polypeptides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-05-10 | — | — | EP | disclosed |
| EP-0230266-A2 | Functionalized peptidyl aminodiols and -triols | ABBOTT LABORATORIES (US) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312646-A1 | ANTIBACTERIAL PEPTIDES | VIP, NRDC, CLPP | ALDH1A1 4808/4885MME 117/4885SIGMAR1 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.